Chemours Co: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Nov 3, 2017 and accepted by EDGAR at Nov 3, 2017, 16:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Gross profit | 3 months2017-07-01 to 2017-09-30 | $467.0m | us-gaap:GrossProfit |
| Gross profit | 9 months2017-01-01 to 2017-09-30 | $1.27bn | us-gaap:GrossProfit |
| Research and development | 3 months2017-07-01 to 2017-09-30 | $20.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $61.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $148.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $444.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2017-07-01 to 2017-09-30 | $55.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2017-01-01 to 2017-09-30 | $161.0m | us-gaap:InterestExpense |
| Income tax | 3 months2017-07-01 to 2017-09-30 | $43.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | $130.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | $207.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | $518.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | $1.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | $2.72 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | $1.12 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | $2.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 191,637,814 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 190,550,614 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $336.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $246.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2017-01-01 to 2017-09-30 | $16.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2017-09-30 | $1.53bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $3.43bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $7.12bn | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $1.57bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $6.32bn | us-gaap:Liabilities |
| Long-term debt | At period end2017-09-30 | $4.08bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2017-09-30 | $14.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2017-09-30 | $800.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-17-021527. Last ingested by Listed: Nov 5, 2026, 19:57 ET. Listed shows no prices and gives no investment advice.